Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent a growing global health problem linked to obesity, insulin resistance, and dyslipidemia. MASLD often leads to fibrosis, cirrhosis, and hepatoc...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
MDPI AG
2025-02-01
|
| Schriftenreihe: | Current Issues in Molecular Biology |
| Schlagworte: | |
| Online-Zugang: | https://www.mdpi.com/1467-3045/47/3/154 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|